Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.21
NUVA's Cash-to-Debt is ranked lower than
86% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.55 vs. NUVA: 0.21 )
Ranked among companies with meaningful Cash-to-Debt only.
NUVA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.21  Med: 0.84 Max: No Debt
Current: 0.21
Equity-to-Asset 0.44
NUVA's Equity-to-Asset is ranked lower than
75% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. NUVA: 0.44 )
Ranked among companies with meaningful Equity-to-Asset only.
NUVA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.36  Med: 0.49 Max: 0.93
Current: 0.44
0.36
0.93
Interest Coverage 3.21
NUVA's Interest Coverage is ranked lower than
90% of the 222 Companies
in the Global Medical Devices industry.

( Industry Median: 86.37 vs. NUVA: 3.21 )
Ranked among companies with meaningful Interest Coverage only.
NUVA' s Interest Coverage Range Over the Past 10 Years
Min: 0.65  Med: 2.32 Max: No Debt
Current: 3.21
Piotroski F-Score: 5
Altman Z-Score: 3.57
Beneish M-Score: -2.35
WACC vs ROIC
8.31%
6.54%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 13.49
NUVA's Operating Margin % is ranked higher than
76% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. NUVA: 13.49 )
Ranked among companies with meaningful Operating Margin % only.
NUVA' s Operating Margin % Range Over the Past 10 Years
Min: -15.73  Med: 3.95 Max: 17.15
Current: 13.49
-15.73
17.15
Net Margin % 5.35
NUVA's Net Margin % is ranked higher than
56% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.55 vs. NUVA: 5.35 )
Ranked among companies with meaningful Net Margin % only.
NUVA' s Net Margin % Range Over the Past 10 Years
Min: -12.92  Med: 0.83 Max: 16.37
Current: 5.35
-12.92
16.37
ROE % 7.72
NUVA's ROE % is ranked higher than
57% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. NUVA: 7.72 )
Ranked among companies with meaningful ROE % only.
NUVA' s ROE % Range Over the Past 10 Years
Min: -15.05  Med: 1 Max: 21.43
Current: 7.72
-15.05
21.43
ROA % 3.35
NUVA's ROA % is ranked higher than
58% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 0.06 vs. NUVA: 3.35 )
Ranked among companies with meaningful ROA % only.
NUVA' s ROA % Range Over the Past 10 Years
Min: -7.72  Med: 0.47 Max: 10.76
Current: 3.35
-7.72
10.76
ROC (Joel Greenblatt) % 31.74
NUVA's ROC (Joel Greenblatt) % is ranked higher than
75% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 4.26 vs. NUVA: 31.74 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NUVA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -42.62  Med: 10.28 Max: 47.3
Current: 31.74
-42.62
47.3
3-Year Revenue Growth Rate 6.70
NUVA's 3-Year Revenue Growth Rate is ranked higher than
57% of the 237 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. NUVA: 6.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NUVA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -40.2  Med: 12.55 Max: 480.7
Current: 6.7
-40.2
480.7
3-Year EBITDA Growth Rate 21.60
NUVA's 3-Year EBITDA Growth Rate is ranked higher than
73% of the 208 Companies
in the Global Medical Devices industry.

( Industry Median: 5.10 vs. NUVA: 21.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NUVA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -36.3 Max: 24.4
Current: 21.6
0
24.4
3-Year EPS without NRI Growth Rate 59.50
NUVA's 3-Year EPS without NRI Growth Rate is ranked higher than
89% of the 203 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. NUVA: 59.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NUVA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -66.3  Med: -30.4 Max: 162.1
Current: 59.5
-66.3
162.1
GuruFocus has detected 3 Warning Signs with NuVasive Inc $NUVA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NUVA's 30-Y Financials

Financials (Next Earnings Date: 2017-07-25 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

NUVA Guru Trades in Q2 2016

Pioneer Investments 63,589 sh (+87.94%)
Jim Simons 319,188 sh (+22.67%)
Ken Fisher 1,412,861 sh (+0.15%)
Mario Gabelli 167,000 sh (-1.76%)
PRIMECAP Management 869,600 sh (-3.49%)
RS Investment Management 784,483 sh (-23.96%)
Steven Cohen 242,400 sh (-64.08%)
Paul Tudor Jones 3,712 sh (-82.96%)
Eaton Vance Worldwide Health Sciences Fund 344,200 sh (-57.30%)
» More
Q3 2016

NUVA Guru Trades in Q3 2016

Jana Partners 80,744 sh (New)
Paul Tudor Jones 5,600 sh (+50.86%)
Pioneer Investments 70,786 sh (+11.32%)
Ken Fisher 1,422,585 sh (+0.69%)
Steven Cohen Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
PRIMECAP Management 869,000 sh (-0.07%)
Mario Gabelli 165,000 sh (-1.20%)
Jim Simons 129,600 sh (-59.40%)
» More
Q4 2016

NUVA Guru Trades in Q4 2016

Andreas Halvorsen 695,707 sh (New)
Jana Partners 1,810,169 sh (+2141.86%)
Paul Tudor Jones Sold Out
Jim Simons Sold Out
Mario Gabelli 162,500 sh (-1.52%)
Ken Fisher 1,398,259 sh (-1.71%)
PRIMECAP Management 853,900 sh (-1.74%)
Pioneer Investments 31,754 sh (-55.14%)
» More
Q1 2017

NUVA Guru Trades in Q1 2017

Paul Tudor Jones 9,388 sh (New)
Jim Simons 57,188 sh (New)
Steven Cohen 94,800 sh (New)
Caxton Associates 6,700 sh (New)
Pioneer Investments 64,654 sh (+103.61%)
Andreas Halvorsen 1,232,532 sh (+77.16%)
PRIMECAP Management 853,000 sh (-0.11%)
Mario Gabelli 161,555 sh (-0.58%)
Ken Fisher 1,354,648 sh (-3.12%)
Jana Partners 1,201,837 sh (-33.61%)
» More
» Details

Insider Trades

Latest Guru Trades with NUVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:NAS:IART, OTCPK:SHWGY, OTCPK:EKTAY, OTCPK:FSPKF, OTCPK:GGNDF, NYSE:GMED, OTCPK:AMBFF, NAS:WMGI, NAS:LIVN, NAS:MASI, NYSE:PEN, NAS:ZLTQ, NYSE:NVRO, OTCPK:NHNKY, NAS:INGN, OTCPK:IOBCF, NAS:CYNO, NAS:MDXG, NAS:CNMD, NAS:ABMD » details
Traded in other countries:NK8.Germany,
Headquarter Location:USA
NuVasive Inc is a medical device company. The Company develops minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its currently-marketed product portfolio is focused on applications for spine fusion surgery.

NuVasive is a medical-device company focused on minimally invasive surgical products and integrated solutions for spine surgery. The firm's spine surgery products contribute the majority of revenue. Its key offering is the maximum access surgery minimally disruptive surgical platform, which minimizes soft-tissue disruption and contact with critical nerves and maximizes visualization during spine fusion surgery. NuVasive also develops biologics used to aid in the spinal fusion or bone-healing processes, such as a collagen-based synthetic bone substitute and synthetic bone-graft material. NuVasive generates the majority of its revenue in the United States.

Top Ranked Articles about NuVasive Inc

Insiders Load Up on NuVasive as Price Tumbles 3 company insiders collectively purchase 26,172 shares
Multiple insiders of NuVasive (NUVA) purchased a total of 26,172 insider shares this week. Read more...

Ratios

vs
industry
vs
history
PE Ratio 78.22
NUVA's PE Ratio is ranked lower than
93% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 27.53 vs. NUVA: 78.22 )
Ranked among companies with meaningful PE Ratio only.
NUVA' s PE Ratio Range Over the Past 10 Years
Min: 11.39  Med: 77.69 Max: 387.67
Current: 78.22
11.39
387.67
Forward PE Ratio 37.59
NUVA's Forward PE Ratio is ranked lower than
82% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 21.79 vs. NUVA: 37.59 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 78.22
NUVA's PE Ratio without NRI is ranked lower than
94% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 27.51 vs. NUVA: 78.22 )
Ranked among companies with meaningful PE Ratio without NRI only.
NUVA' s PE Ratio without NRI Range Over the Past 10 Years
Min: 11.39  Med: 77.69 Max: 387.67
Current: 78.22
11.39
387.67
PB Ratio 5.56
NUVA's PB Ratio is ranked lower than
75% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.11 vs. NUVA: 5.56 )
Ranked among companies with meaningful PB Ratio only.
NUVA' s PB Ratio Range Over the Past 10 Years
Min: 0.98  Med: 3.67 Max: 10.89
Current: 5.56
0.98
10.89
PS Ratio 4.27
NUVA's PS Ratio is ranked lower than
61% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. NUVA: 4.27 )
Ranked among companies with meaningful PS Ratio only.
NUVA' s PS Ratio Range Over the Past 10 Years
Min: 0.86  Med: 3.19 Max: 10.65
Current: 4.27
0.86
10.65
Price-to-Free-Cash-Flow 255.58
NUVA's Price-to-Free-Cash-Flow is ranked lower than
84% of the 112 Companies
in the Global Medical Devices industry.

( Industry Median: 27.61 vs. NUVA: 255.58 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
NUVA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.98  Med: 52.7 Max: 687.63
Current: 255.58
6.98
687.63
Price-to-Operating-Cash-Flow 33.11
NUVA's Price-to-Operating-Cash-Flow is ranked lower than
62% of the 140 Companies
in the Global Medical Devices industry.

( Industry Median: 20.26 vs. NUVA: 33.11 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
NUVA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.77  Med: 19 Max: 372.21
Current: 33.11
4.77
372.21
EV-to-EBIT 32.50
NUVA's EV-to-EBIT is ranked lower than
76% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 24.54 vs. NUVA: 32.50 )
Ranked among companies with meaningful EV-to-EBIT only.
NUVA' s EV-to-EBIT Range Over the Past 10 Years
Min: -166  Med: 25 Max: 559.6
Current: 32.5
-166
559.6
EV-to-EBITDA 17.79
NUVA's EV-to-EBITDA is ranked lower than
56% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 19.31 vs. NUVA: 17.79 )
Ranked among companies with meaningful EV-to-EBITDA only.
NUVA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -325.2  Med: 16.1 Max: 4339.7
Current: 17.79
-325.2
4339.7
Shiller PE Ratio 573.55
NUVA's Shiller PE Ratio is ranked lower than
96% of the 50 Companies
in the Global Medical Devices industry.

( Industry Median: 49.41 vs. NUVA: 573.55 )
Ranked among companies with meaningful Shiller PE Ratio only.
NUVA' s Shiller PE Ratio Range Over the Past 10 Years
Min: 538.66  Med: 751.58 Max: 842.75
Current: 573.55
538.66
842.75
Current Ratio 2.40
NUVA's Current Ratio is ranked higher than
50% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 2.38 vs. NUVA: 2.40 )
Ranked among companies with meaningful Current Ratio only.
NUVA' s Current Ratio Range Over the Past 10 Years
Min: 1.58  Med: 5.22 Max: 15.05
Current: 2.4
1.58
15.05
Quick Ratio 1.45
NUVA's Quick Ratio is ranked lower than
58% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. NUVA: 1.45 )
Ranked among companies with meaningful Quick Ratio only.
NUVA' s Quick Ratio Range Over the Past 10 Years
Min: 1.14  Med: 3.93 Max: 13.9
Current: 1.45
1.14
13.9
Days Inventory 308.75
NUVA's Days Inventory is ranked lower than
84% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 130.04 vs. NUVA: 308.75 )
Ranked among companies with meaningful Days Inventory only.
NUVA' s Days Inventory Range Over the Past 10 Years
Min: 266.24  Med: 334.46 Max: 491.78
Current: 308.75
266.24
491.78
Days Sales Outstanding 63.02
NUVA's Days Sales Outstanding is ranked higher than
56% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 68.94 vs. NUVA: 63.02 )
Ranked among companies with meaningful Days Sales Outstanding only.
NUVA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 52.35  Med: 58.06 Max: 75.34
Current: 63.02
52.35
75.34
Days Payable 13.45
NUVA's Days Payable is ranked lower than
92% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 59.71 vs. NUVA: 13.45 )
Ranked among companies with meaningful Days Payable only.
NUVA' s Days Payable Range Over the Past 10 Years
Min: 12.75  Med: 27.32 Max: 63.36
Current: 13.45
12.75
63.36

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.90
NUVA's 3-Year Average Share Buyback Ratio is ranked higher than
51% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. NUVA: -3.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NUVA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -215.4  Med: -5 Max: -3.8
Current: -3.9
-215.4
-3.8

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 4.76
NUVA's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
74% of the 129 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. NUVA: 4.76 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
NUVA' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.2  Med: 2.66 Max: 18.72
Current: 4.76
1.2
18.72
Price-to-Median-PS-Value 1.33
NUVA's Price-to-Median-PS-Value is ranked lower than
69% of the 242 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. NUVA: 1.33 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NUVA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.3  Med: 1.04 Max: 2.81
Current: 1.33
0.3
2.81
Earnings Yield (Greenblatt) % 3.04
NUVA's Earnings Yield (Greenblatt) % is ranked higher than
54% of the 432 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. NUVA: 3.04 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NUVA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.2  Med: 2.4 Max: 6.8
Current: 3.04
0.2
6.8

More Statistics

Revenue (TTM) (Mil) $996.8
EPS (TTM) $ 0.97
Beta1.10
Short Percentage of Float10.26%
52-Week Range $53.06 - 77.88
Shares Outstanding (Mil)50.66

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1,067 1,156 1,244
EPS ($) 2.02 2.46 2.91
EPS without NRI ($) 2.02 2.46 2.91
EPS Growth Rate
(Future 3Y To 5Y Estimate)
19.10%
Dividends per Share ($)
» More Articles for NUVA

Headlines

Articles On GuruFocus.com
NuVasive Announces Educational Initiatives In Support Of Spine's Fastest Growing Spinal Deformity Po May 22 2017 
NuVasive To Present At Bank of America Merrill Lynch 2017 Global Healthcare Conference May 09 2017 
NuVasive Announces Sponsorship Of EPOSNA 2017 And Launches New Monthly Pediatric Spinal Deformity Po May 02 2017 
NuVasive Unveils New Trauma Portfolio And Virtual Reality Simulation At AANS 2017 Apr 20 2017 
NuVasive Launches New Spinal Trauma Portfolio Apr 19 2017 
NuVasive To Feature Proprietary Radiation Reduction Platform At ISASS 2017 Apr 12 2017 
NuVasive Announces Conference Call And Webcast Of First Quarter 2017 Results Apr 10 2017 
NuVasive Receives First-Ever FDA Clearance For Cervical Interbody Implant System Used In More Than T Mar 31 2017 
Jana Partners' Largest 4th-Quarter Buys Mar 01 2017 
Insiders Load Up on NuVasive as Price Tumbles Nov 03 2016 

More From Other Websites
NuVasive, Inc. breached its 50 day moving average in a Bullish Manner : NUVA-US : May 26, 2017 May 26 2017
NuVasive Announces Educational Initiatives In Support Of Spine's Fastest Growing Spinal Deformity... May 22 2017
NuVasive To Present At Bank of America Merrill Lynch 2017 Global Healthcare Conference May 09 2017
ETFs with exposure to NuVasive, Inc. : May 8, 2017 May 08 2017
NuVasive Announces Sponsorship Of EPOSNA 2017 And Launches New Monthly Pediatric Spinal Deformity... May 02 2017
Edited Transcript of NUVA earnings conference call or presentation 25-Apr-17 8:30pm GMT Apr 29 2017
NuVasive, Inc. :NUVA-US: Earnings Analysis: Q1, 2017 By the Numbers : April 27, 2017 Apr 27 2017
NuVasive (NUVA) Beats on Q1 Earnings, Retains 2017 View Apr 26 2017
NuVasive Straightens Up With Solid Growth Apr 25 2017
NuVasive beats 1Q profit forecasts Apr 25 2017
NuVasive Announces First Quarter 2017 Financial Results Apr 25 2017
Here’s how much NuVasive’s 5 highest-paid executives earned Apr 25 2017
Lawsuit for Investors in NASDAQ:NUVA Shares against Directors of NuVasive, Inc Announced by... Apr 24 2017
NuVasive, Inc. – Value Analysis (NASDAQ:NUVA) : April 21, 2017 Apr 21 2017
NuVasive (NUVA) Q1 Earnings: Disappointment in the Cards? Apr 21 2017
NuVasive Unveils New Trauma Portfolio And Virtual Reality Simulation At AANS 2017 Apr 20 2017
NuVasive launching products to hit $100M market Apr 20 2017
NuVasive, Inc. breached its 50 day moving average in a Bullish Manner : NUVA-US : April 20, 2017 Apr 20 2017
NuVasive Launches New Spinal Trauma Portfolio Apr 19 2017
NuVasive To Feature Proprietary Radiation Reduction Platform At ISASS 2017 Apr 12 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)